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Biosimilars need comparative
clinical data
To the Editor: We have read with great interest the study by
Praditpornsilpa et al.1 in Kidney International about the
association between antibody-associated pure red cell aplasia
(PRCA) and the use of copies of epoetins alpha and beta, for
which the marketing authorization was based on the generic
regulatory approach used for small molecules, which does not
demand comparative clinical data.
We noticed the statement of the editor accompanying this
paper deﬁning ‘biosimilar’ as ‘a term applied to subsequent
versions of biopharmaceutical products that have been
approved by the regulatory authorities of a given country.
The pathway for approval is thus speciﬁc for that country,
and because of regulatory differences, the biosimilar classiﬁ-
cation may not apply in other countries.’
This statement suggests that any subsequent biopharma-
ceutical that is authorized by any national regulatory pathway
can be considered a biosimilar. However, there is a worldwide
consensus that a biosimilar is a biopharmaceutical accepted
by a regulatory pathway requiring clinical and biological
comparison with the original product and also the evaluation
of the immunogenic potential. These requirements are
included in the World Health Organization guidelines
concerning biosimilars, which is considered the minimal
worldwide condition for market approval.2 Based on these
principles, the use of the term ‘biosimilars’ in the paper by
Praditpornsilpa et al. should be reconsidered.
We also strongly support the prospective study planned by
our colleagues in Thailand that will enable linking the
immunogenicity with speciﬁc erythropoiesis-stimulating
agents. This study will help us to understand the cause of
epoetin-associated PRCA and to further develop the regula-
tory pathways for biosimilars. For this type of study and its
publication, standardization is essential, not only of termino-
logy but also of antibody assays and of the clinical diagnosis
of antibody-associated PRCA.
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KDIGO clinical practice guidelines
for bisphosphonate treatment
in chronic kidney disease
To the Editor: We have read the letter to the editor by Jerzy
Przedlacki1 and the response from the authors2 of the Kidney
Disease-Improving Global Outcomes (KDIGO) clinical prac-
tice guidelines for bisphosphonate (BP) treatment in chronic
kidney disease (CKD), and would like to share our concerns
regarding the use of BP treatment of CKD. The kidney is the
organ that excretes many drugs, and any change in renal
function will affect the pharmacology of these drugs. Existing
or residual renal function of the patient will have to be taken
into account while prescribing drugs. This is just as important
for the patient with CKD 4 or 5, including those with CKD 5
already on peritoneal dialysis or hemodialysis, who may still
have residual renal function. Nephrotoxic drugs including
nonsteroidal anti-inﬂammatory drugs can very readily
destroy whatever residual renal function patients may still
have. Residual renal function is important to preserve as it
contributes to less patient morbidity and mortality3 in the
dialysis patient. Recently, there have been adverse reports of a
certain BP that works by inhibiting osteoclast-mediated bone
resorption, thereby slowing the breakdown of bone to reduce
the risk of fractures. As of 14 August 2009, there have been
139 post-marketing reports of renal impairment following
its use as an infusion worldwide. Many of these occur in
patients with pre-existing medical conditions or risk factors
(elderly, renal impairment, and/or concurrent dehydration),
or in those on nonsteroidal anti-inﬂammatory drugs or other
concurrent exposure to other nephrotoxic agents. There have
also been cases requiring dialysis, and occasional fatal
outcomes have been reported in patients with pre-existing
renal impairment and concomitant risk factors.4–7
In our own nephrology practice within a large acute
tertiary hospital where we have a large referral base, over the
past few years, we have seen several documented cases of
patients with CKD 3 and 4 ending up on dialysis after the use
of BP infusions, even though our orthopedic colleagues had
followed the literature inserts of checking the renal function
before the administration of the BPs. In a few instances,
however, only the serum creatinine was checked without an
estimated glomerular ﬁltration rate staging of CKD until
referral to a renal physician. As mentioned by Dr Przedlacki,
there are many unanswered questions regarding BP, which
need to be answered before the formulation of proper
guidelines. We believe that caution should be exercised for
patients with CKD 3A with estimated glomerular ﬁltration
rate 59–45ml/min and for those with CKD 3B with estimated
glomerular ﬁltration rate o45ml/min. BP should not be
administered until we have adequate data pending
further studies. An estimated glomerular ﬁltration rate of
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30–35ml/min as stated in the present KDIGO clinical practice
guidelines may be too low.
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The Authors Reply: For patients with chronic kidney disease
stage 3 without evidence of bone or mineral disorder,
the Kidney Disease Improving Global Outcomes workgroup
recommended treatment for osteoporosis as in the general
population. Over 80% of women with osteoporosis have
chronic kidney disease stage 3 or 4 (ref. 1). Most of these
elderly patients with age-related chronic kidney disease are
not examined by nephrologists. In determining appropriate
therapy for osteoporosis, the reduction in hip fracture and,
potentially, in mortality, must be balanced against adverse
events. In the pivotal trials of zoledronic acid, a transient
increase in serum creatinine was noted in 1.3% of the
patients on the drug and in 0.4% on placebo in 3889
osteoporotic patients.2 In a study of 1065 patients with a
recent hip fracture, an increase in serum creatinine was seen
in 6.2% of patients on the drug and 5.6% on placebo. There
was a 28% reduction in overall mortality with the drug.3
As Dr Woo has written, there are some newer reports
of renal damage that have emerged from post-marketing
surveillance.4 However, the incidence of these adverse events
is still low, 18 per 100,000 per year, and most of the patients
had only a transient increase in creatinine. Thus, preventing
the devastating consequences of a hip fracture will usually
outweigh this small risk of kidney damage. To reduce the risk,
physicians should follow guidelines about infusion rates,
avoid volume depletion, or the administration of concomitant
nephrotoxic medications. In addition, using oral dosing may
help reduce this risk.
Once the kidney disease has progressed to chronic kidney
disease–mineral and bone disorder (which is not determined
by the estimated glomerular ﬁltration rate but by abnormal-
ities in calcium, phosphate, parathyroid hormone, or alkaline
phosphatase), there is very little evidence about either safety
or efﬁcacy because these patients were excluded from
the clinical trials. Therefore, we could not recommend the
use of these drugs in the Kidney Disease Improving Global
Outcomes guidelines. These patients must be treated on
an individual basis, and we agree that the possibility of
aggravated progression of renal disease should now be taken
into consideration.
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Hypophosphatemia in patients
with autosomal dominant
polycystic kidney disease: the role
of fibroblast growth factor 23 or
loss of sodium/phosphate
cotransporter?
To the Editor: We read with great interest the contribution
by Pavik et al.1 They reported increased ﬁbroblast growth
factor 23 (FGF23) and decreased serum phosphate levels in
autosomal dominant polycystic kidney disease (ADPKD), and
speculated the association between FGF23 and increased
renal phosphate excretion. We would like to suggest another
possible mechanism of hypophosphatemia in ADPKD
patients.
According to an in vivo study by Vogel et al.,2 the type II
sodium/phosphate cotransporter (NaPi-2) in the brush
border membrane (BBM) of proximal tubules has the central
role of renal phosphate (Pi) absorption. During progression
of ADPKD, the proximal nephron is damaged by the
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